Korean biotech seeks breakthrough in ADC development
Korean biotech firms discuss strategies to compete with China in ADC development, focusing on overcoming resistance and differentiation at Samsung Seoul Hospital conference.
ABL Bio terminates ADC platform tech deal with Intocell
ABL Bio terminated its ADC platform technology licensing agreement with Intocell due to potential patent infringement issues. The company states this won't affect its pipeline development schedules.
ABL Bio terminates ADC platform technology contract with Intocell
ABL Bio terminates ADC platform technology contract with Intocell due to patent issues. The company will continue developing ADC pipelines using Synaffix's technology.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.